{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:14:31Z","timestamp":1788974071626,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"DOI":"10.1007\/s43441-026-01044-5","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:42:06Z","timestamp":1788972126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contribution of Real-World Evidence for the Orphan Medicines Approvals in the European Union Between 2000 and 2025"],"prefix":"10.1007","author":[{"given":"Lu\u00edsa","family":"Bouwman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sepodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-9993","authenticated-orcid":false,"given":"Carla","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"1044_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-025-01528-7","author":"F Windfuhr","year":"2025","unstructured":"Windfuhr F, et al. Stakeholders\u2019 perspectives toward the use of patient registry data for decision-making on medicines: a cross-sectional survey. Drug Saf. 2025. https:\/\/doi.org\/10.1007\/s40264-025-01528-7.","journal-title":"Drug Saf"},{"issue":"1","key":"1044_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/cpt.2462","volume":"111","author":"SM Eskola","year":"2022","unstructured":"Eskola SM, Leufkens HGM, Bate A, De Bruin ML, Gardarsdottir H. Use of real-world data and evidence in drug development of medicinal products centrally authorized in Europe in 2018\u20132019. Clin Pharmacol Ther. 2022;111(1):310\u201320. https:\/\/doi.org\/10.1002\/cpt.2462.","journal-title":"Clin Pharmacol Ther"},{"key":"1044_CR3","unstructured":"European Medicines Agency, \u201cCommittee for medicinal products for human use and ICH reflection paper on pursuing opportunities for harmonisation in using real-world data to generate real-world evidence, with a focus on effectiveness of medicines (EMA\/CHMP\/ICH\/295401\/2023),\u201d 2024. Accessed: Apr. 07, 2025. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-reflection-paper-pursuing-opportunities-harmonisation-using-real-world-data-generate-realworld-evidence-focus-effectiveness-medicines_en.pdf"},{"key":"1044_CR4","doi-asserted-by":"publisher","DOI":"10.1201\/9780429398674","author":"H Yang","year":"2021","unstructured":"Yang H, Yu B. Real-world evidence in drug development and evaluation. Chapman and Hall\/CRC. 2021. https:\/\/doi.org\/10.1201\/9780429398674.","journal-title":"Chapman and Hall\/CRC"},{"key":"1044_CR5","volume-title":"Real-world evidence in the pharmaceutical landscape","author":"S Dravida","year":"2021","unstructured":"Dravida S, Dabral A, Sharma J, Ye Q, Kuyyamudira CK. Real-world evidence in the pharmaceutical landscape. Gatekeeper Press; 2021."},{"key":"1044_CR6","doi-asserted-by":"crossref","unstructured":"Kostis JB, Dobrzynski JM. 2020 Limitations of randomized clinical trials. The American J Cardiol 129 109-15.","DOI":"10.1016\/j.amjcard.2020.05.011"},{"key":"1044_CR7","doi-asserted-by":"publisher","DOI":"10.1353\/pbm.2005.0092","author":"J Grossman","year":"2005","unstructured":"Grossman J, Mackenzie FJ. The randomized controlled trial: gold standard, or merely standard? Perspect Biol Med. 2005. https:\/\/doi.org\/10.1353\/pbm.2005.0092.","journal-title":"Perspect Biol Med"},{"key":"1044_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2011.05.024","author":"CW Jones","year":"2012","unstructured":"Jones CW, Platts-Mills TF. Understanding commonly encountered limitations in clinical research: an emergency medicine resident\u2019s perspective. Ann Emerg Med. 2012. https:\/\/doi.org\/10.1016\/j.annemergmed.2011.05.024.","journal-title":"Ann Emerg Med"},{"key":"1044_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050067","author":"JP Vandenbroucke","year":"2008","unstructured":"Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS ONE. 2008. https:\/\/doi.org\/10.1371\/journal.pmed.0050067.","journal-title":"PLoS ONE"},{"issue":"4","key":"1044_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/cpt.1351","volume":"105","author":"JM Franklin","year":"2019","unstructured":"Franklin JM, Glynn RJ, Martin D, Schneeweiss S. Evaluating the use of nonrandomized real-world data analyses for regulatory decision making. Clin Pharmacol Ther. 2019;105(4):867\u201377. https:\/\/doi.org\/10.1002\/cpt.1351.","journal-title":"Clin Pharmacol Ther"},{"key":"1044_CR11","unstructured":"European Medicines Agency. 2020 EMA regulatory science to 2025: strategic reflection."},{"key":"1044_CR12","unstructured":"D. M. Center for Health Policy Center for Health Policy. 2019 Adding real-world evidence to a totality of evidence approach for evaluating marketed product effectiveness."},{"key":"1044_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2083","author":"HG Eichler","year":"2021","unstructured":"Eichler HG, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021. https:\/\/doi.org\/10.1002\/cpt.2083.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1044_CR14","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/cpt.2103","volume":"110","author":"P Varnai","year":"2021","unstructured":"Varnai P, Dav\u00e9 A, Farla K, Nooijen A, Petrosova L. The evidence REVEAL study: exploring the use of real-world evidence and complex clinical trial design by the European pharmaceutical industry. Clin Pharmacol Ther. 2021;110(5):1180\u20139. https:\/\/doi.org\/10.1002\/cpt.2103.","journal-title":"Clin Pharmacol Ther"},{"key":"1044_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1426","author":"A Cave","year":"2019","unstructured":"Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019. https:\/\/doi.org\/10.1002\/cpt.1426.","journal-title":"Clin Pharmacol Ther"},{"key":"1044_CR16","doi-asserted-by":"crossref","unstructured":"Collins R, Bowman L, Landray M, Peto R. 2020 The magic of randomization versus the myth of real-world evidence. New England J Med 382(7):674-8.","DOI":"10.1056\/NEJMsb1901642"},{"key":"1044_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.12.010","author":"S Mofid","year":"2022","unstructured":"Mofid S, Bolislis WR, K\u00fchler TC. Real-world data in the postapproval setting as applied by the EMA and the US FDA. Clin Ther. 2022. https:\/\/doi.org\/10.1016\/j.clinthera.2021.12.010.","journal-title":"Clin Ther"},{"issue":"1","key":"1044_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/cpt.2462","volume":"111","author":"SM Eskola","year":"2022","unstructured":"Eskola SM, Leufkens HGM, Bate A, De Bruin ML, Gardarsdottir H. Use of real-world data and evidence in drug development of medicinal products centrally authorized in Europe in 2018\u20132019. Clin Pharmacol Ther. 2022;111(1):310\u201320.","journal-title":"Clin Pharmacol Ther"},{"key":"1044_CR19","doi-asserted-by":"crossref","unstructured":"Flynn R, Plueschke K, Quinten C, Strassmann V, Duijnhoven RG, Gordillo\u2010Mara\u00f1on M, Rueckbeil M, Cohet C, Kurz X. 2022 Marketing authorization applications made to the European medicines agency in 2018\u20132019: what was the contribution of real\u2010world evidence?. Clinical Pharmacol Therapeutics. 111(1):90-7.","DOI":"10.1002\/cpt.2461"},{"key":"1044_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03095-z","author":"L Bouwman","year":"2010","unstructured":"Bouwman L, Sepodes B, Leufkens H, Torre C. Trends in orphan medicinal products approvals in the European Union between 2010\u20132022. Orphanet J Rare Dis. 2010. https:\/\/doi.org\/10.1186\/s13023-024-03095-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1044_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cpt.2766","volume":"113","author":"E Bakker","year":"2023","unstructured":"Bakker E, Plueschke K, Jonker CJ, Kurz X, Starokozhko V, Mol PGM. Contribution of real-world evidence in European Medicines Agency\u2019s regulatory decision making. Clin Pharmacol Ther. 2023;113(1):135\u201351. https:\/\/doi.org\/10.1002\/cpt.2766.","journal-title":"Clin Pharmacol Ther"},{"key":"1044_CR22","unstructured":"European Medicines Agency, \u201cReflection paper on use of real-world data in non-interventional studies to generate real-world evidence for regulatory purposes (EMA\/99865\/2025). https:\/\/www.ema.europa.eu\/en\/documents\/other\/reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence-regulatory-purposes_en.pdf. Accessed 07 Apr 2025."},{"key":"1044_CR23","unstructured":"\u201cRegulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32014R0536 Accessed 22 Mar 2025."},{"key":"1044_CR24","unstructured":"\u201cEuropean Medicines Agency (EMA): Search Medicines Database\u201d, Accessed: Jan. 21, 2025. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/search."},{"key":"1044_CR25","unstructured":"European Medicines Agency, \u201cEMA Annual reports and working programmes. https:\/\/www.ema.europa.eu\/en\/about-us\/annual-reports-work-programmes Accessed 11 Apr 2026."},{"key":"1044_CR26","unstructured":"European Medicines Agency (EMA), \u201cPost-authorisation measures: questions and answers.\u201d Accessed: Apr. 21, 2025. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/pharmacovigilance-post-authorisation\/post-authorisation-measures-questions-and-answers#pdf-versions-of-qa-theentire-post-authorisation-guidance-8254"},{"key":"1044_CR27","unstructured":"European Medicines Agency. EMA\/426390\/2021. Guideline on registry-based studies. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-registry-based-studies_en.pdf 2021. Accessed 08 Nov. 2025."},{"key":"1044_CR28","unstructured":"European Medicines Agency, \u201cEMA\/176050\/2014. Initiative for patient registries Strategy and pilot phase. https:\/\/www.ema.europa.eu\/en\/documents\/other\/initiative-patient-registries-strategy-and-pilot-phase_en.pdf 2015. Accessed 08 Nov 2025."},{"key":"1044_CR29","unstructured":"HMA-EMA, \u201cRWD Catalogues of real-world data sources and studies. https:\/\/catalogues.ema.europa.eu\/2025. Accessed 20 Apr 2025."},{"key":"1044_CR30","unstructured":"\u201cCommission Implementing Regulation EU (No) 520\/2012 of 19 June 2012 on the performance of pharmacovigilance activities provided for in Regulation (EC) No 726\/2004 of the European Parliament and of the Council and Directive 20021\/83\/EC of the European Parliament and of the Council. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:02012R0520-20250812 2012. Accessed: Mar. 27, 2026."},{"key":"1044_CR31","unstructured":"\u201cRegulation (EC) No 141\/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal product. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32000R0141 Accessed: Jan. 21, 2025."},{"key":"1044_CR32","doi-asserted-by":"crossref","unstructured":"Parums DV. 2025 A review of the importance and relevance of real-world data and real-world evidence. Med Sci Monitor: Inter Med J Experimental Clinical Res 31:e951118.","DOI":"10.12659\/MSM.951118"},{"key":"1044_CR33","unstructured":"The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH), \u201cchoice of control group and related issues in clinical trials (E10). https:\/\/database.ich.org\/sites\/default\/files\/E10_Guideline.pdf 2000. Accessed: Jan. 09, 2026."},{"key":"1044_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3684","author":"M Russek","year":"2025","unstructured":"Russek M, Peltner J, Haenisch B. Supplementing single-arm trials with external control arms\u2014evaluation of German real-world data. Clin Pharmacol Ther. 2025. https:\/\/doi.org\/10.1002\/cpt.3684.","journal-title":"Clin Pharmacol Ther"},{"key":"1044_CR35","unstructured":"European Medicines Agency, \u201cDraft concept paper on the development of a reflection paper on the use of external controls for evidence generation in regulatory decision-making. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-concept-paper-development-reflection-paper-use-external-controls-evidence-generation-regulatory-decision-making_en.pdf 2025. Accessed: Nov. 08, 2025."},{"key":"1044_CR36","unstructured":"\u201cMHRA draft guideline on the use of external control arms based on real-world data to support regulatory decisions. https:\/\/assets.publishing.service.gov.uk\/media\/6825bab1a4c1a40fde4e63e5\/Draft_MHRA_Guideline_on_Studies_with_RWD_ECA_May2025.pdf 2025, Accessed: Nov. 08, 2025."},{"key":"1044_CR37","unstructured":"Food and Drug Administration, \u201cConsiderations for the design and conduct of externally controlled trials for drug and biological products guidance for industry DRAFT GUIDANCE. https:\/\/www.fda.gov\/media\/164960\/download 2023. Accessed: Nov. 08, 2025. [Online]. Available:"},{"key":"1044_CR38","doi-asserted-by":"publisher","unstructured":"\u201cRegulation (EC) No 726\/2004 of the European parliament and of the council of 31 March 2004. Official J European Union, vol. L 136\/1, 2004, https:\/\/doi.org\/10.4324\/9781843143024-116.","DOI":"10.4324\/9781843143024-116"},{"key":"1044_CR39","unstructured":"\u201cDirective 2001\/83\/EC of the European parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32001L0083 Accessed: Feb. 01, 2025."},{"key":"1044_CR40","unstructured":"\u201cTitle 21-food and drugs chapter I-food and drug administration, department of health and human services subchapter D-drugs for human use part 312-Investigational New Drug Application. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-312\/subpart-I Accessed: Jan. 11, 2026."},{"key":"1044_CR41","unstructured":"D. Wagner, G. Deuchar, M. Dutouya, X. Luria, P. Mott\u00e9, and G. McGettigan, \u201cEarly access in the EU: a heterogeneous landscape with room for harmonisation,\u201d Regulatory Rapporteur, vol. 17, no. 9, Sep. 2020. https:\/\/www.kinesysconsulting.com\/wp-content\/uploads\/2020\/09\/Regulatory-Rapporteur-Sep-2020-Wagner-et-al-EAP_high-res-pdf.pdf Accessed: Jan. 11, 2026."},{"issue":"1","key":"1044_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/2229-3485.173779","volume":"7","author":"S Patil","year":"2016","unstructured":"Patil S. Early access programs: benefits, challenges, and key considerations for successful implementation. Perspect Clin Res. 2016;7(1):4. https:\/\/doi.org\/10.4103\/2229-3485.173779.","journal-title":"Perspect Clin Res"},{"key":"1044_CR43","unstructured":"Committee for medicinal products for human use (CHMP), \u201cEPAR Arikayce liposomal,\u201d 2020. Accessed: Jan. 11, 2026. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/arikayce-liposomal-epar-public-assessment-report_en.pdf"},{"key":"1044_CR44","unstructured":"Committee for Medicinal Products for Human Use (CHMP), \u201cEPAR Rezzayo,\u201d 2023. Accessed: Jan. 11, 2026. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rezzayo-epar-public-assessment-report_en.pdf"},{"key":"1044_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.913567","author":"TB Polak","year":"2022","unstructured":"Polak TB, Cucchi DGJ, van Rosmalen J, Uyl-de Groot CA, Darrow JJ. Generating evidence from expanded access use of rare disease medicines: challenges and recommendations. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.913567.","journal-title":"Front Pharmacol"},{"key":"1044_CR46","unstructured":"Food and Drug Administration. 21 Century Cures Act. https:\/\/www.fda.gov\/regulatory-information\/selected-amendments-fdc-act\/21st-century-cures-act Accessed: Nov. 01, 2025."},{"key":"1044_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2474","author":"CA Purpura","year":"2022","unstructured":"Purpura CA, Garry EM, Honig N, Case A, Rassen JA. The role of real-world evidence in FDA-approved new drug and biologics license applications. Clin Pharmacol Ther. 2022. https:\/\/doi.org\/10.1002\/cpt.2474.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1044_CR48","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","volume":"55","author":"M Jahanshahi","year":"2021","unstructured":"Jahanshahi M, et al. The use of external controls in FDA regulatory decision making. Ther Innov Regul Sci. 2021;55(5):1019\u201335. https:\/\/doi.org\/10.1007\/s43441-021-00302-y.","journal-title":"Ther Innov Regul Sci"},{"key":"1044_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3540","author":"J Asano","year":"2025","unstructured":"Asano J, Sugano H, Murakami H, Noguchi A, Ando Y, Uyama Y. PMDA perspective on use of real-world data and real-world evidence as an external control: recent examples and considerations. Clin Pharmacol Ther. 2025. https:\/\/doi.org\/10.1002\/cpt.3540.","journal-title":"Clin Pharmacol Ther"},{"key":"1044_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-025-00737-x","author":"D Almeida","year":"2013","unstructured":"Almeida D, Mandslay D, Mol PGM, Sepodes B, Torre C. Real-world data included in post-authorisation measures: a case study of approved advanced therapy medicinal products in the European Union between 2013 and 2024. BioDrugs. 2013. https:\/\/doi.org\/10.1007\/s40259-025-00737-x.","journal-title":"BioDrugs"},{"key":"1044_CR51","doi-asserted-by":"crossref","unstructured":"Jonker CJ, Bakker E, Kurz X, Plueschke K. 2022 Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe. Frontiers in Pharmacol. 13:924648.","DOI":"10.3389\/fphar.2022.924648"},{"key":"1044_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.940010","author":"M Mazzucato","year":"2022","unstructured":"Mazzucato M, Minichiello C, Vianello A, Vison\u00e0 dalla Pozza L, Toto E, Facchin P. Real-world use of orphan medicinal products (OMPs) in rare disease (RD) patients: a population-based registry study. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.940010.","journal-title":"Front Pharmacol"},{"key":"1044_CR53","doi-asserted-by":"crossref","unstructured":"Mordenti M, Boarini M, D\u2019Alessandro F, Pedrini E, Locatelli M, Sangiorgi L. 2022 Remodeling an existing rare disease registry to be used in regulatory context: Lessons learned and recommendations. Frontiers in Pharmacology. 13:966081.","DOI":"10.3389\/fphar.2022.966081"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01044-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:42:29Z","timestamp":1788972149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-01044-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":53,"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01044-5","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests. This research is independent and not funded by any organisation. The views expressed in this article represent the author\u2019s own thoughts and are independent of their employers.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No ethical approval was required since no data on animal or human data or tissue were used for this project.","order":2,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}